Mirum Pharmaceuticals, Inc. Soared
Mirum Pharmaceuticals, Inc. (MIRM:NASDAQ) shot up at $23.76, representing a gain of 44.1%. On Tue 17 Dec 19, MIRM:NASDAQ touched a New 2-Week Intraday High of $18.03. The stock got featured on our News Catalysts scanner on Tue 17 Dec 19 at 11:57 AM in the 'BIOTECH' category. From Tue 26 Nov 19, the stock recorded 50.00% Up Days and 53.33% Green Days
About Mirum Pharmaceuticals, Inc. (MIRM:NASDAQ)
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Top 10 Gainers:
- Mirum Pharmaceuticals, Inc. (MIRM:NASDAQ), 44.09%
- McDermott International, Inc. (MDR:NYSE), 37.67%
- Sienna Biopharmaceuticals, Inc. (SNNA:NASDAQ), 30.7%
- Reed's, Inc. (REED:NASDAQ), 30.35%
- Reed's, Inc. (REED:NYSEMKT), 30.35%
- YayYo, Inc. (YAYO:NASDAQ), 30.16%
- Inpixon (INPX:NASDAQ), 29.91%
- PhaseBio Pharmaceuticals, Inc. (PHAS:NASDAQ), 27.57%
- LAIX Inc. (LAIX:NYSE), 25.3%
- TSR, Inc. (TSRI:NASDAQ), 24.83%